Skip to main content
SpringerLink
Log in
Book cover

Opiate Receptors and Antagonists pp 689–708Cite as

The Development of ProNeura Technology for the Treatment of Addictions

  • Chapter

Part of the book series: Contemporary Neuroscience ((CNEURO))

Abstract

The growing problem of addiction across the United States and globally, in particular to pain analgesics, has reached a level never seen before in history. Although treatments for addiction have advanced greatly in recent years, current pharmacotherapies are limited by patient compliance, medication blood levels, abuse and diversion, and adverse effects that limit clinical and patient acceptance. Even with treatment, chronic relapse is more common than abstinence. The ProNeura long-term delivery system discussed in this chapter has the potential to eliminate these limitations and improve existing pharmacotherapies. The ProNeura match-stick-sized implants are inserted subcutaneously, and maintain stable concentrations of medication for 6 months or longer. The system allows individually-tailored doses, and shows few adverse effects. The possibility of diversion and abuse is significantly reduced due to the physician-directed administration of the implants, and the difficulties involved in extracting the medication from the implants. By eliminating the need for frequent dosing, compliance to pharmacotherapy treatment is greatly improved. Patients will gain independence from frequent visits for medication, presenting an ideal opportunity to overcome the challenges associated with pharmacological treatment for addictions.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. World Drug Report 2005. Chawla S, Korenblik A, Kunnen S, Le Pichon T, Nathwana A, Pietschmann T et al. Volume 1: Analysis, pp. 1–82. 2005. Vienna International Centre, Vienna, Austria, United Nations Publication.

    Google Scholar 

  2. Office of Applied Studies. Overview of Findings from the 2003 National Survey on Drug Use and Health. 2004. Rockville, MD, Substance Abuse and Mental Health Services Administration.

    Google Scholar 

  3. SAHMSA. National Survey on Drug Use and Health. 2004.

    Google Scholar 

  4. DAWN — Drug Abuse Warning Network. National Estimates of Drug-Related Emergency Department Visits. 2004. Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services.

    Google Scholar 

  5. Fugelstad A, Agren G, Romelsjo A. Changes in mortality, arrests, and hospitalizations in non-voluntarily treated heroin addicts in relation to methadone treatment. Subst Use Misuse 1998; 33(14):2803–2817.

    Article  CAS  PubMed  Google Scholar 

  6. Hubbard RL, Craddock SG, Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat 2003; 25(3):125–134.

    Article  PubMed  Google Scholar 

  7. Reisine T, Bell GI. Molecular biology of opioid receptors. Trends Neurosci 1993; 16(12): 506–510.

    Article  CAS  PubMed  Google Scholar 

  8. Lewis JW. Buprenorphine. Drug Alcohol Depend 1985; 14(3–4):363–372.

    Article  CAS  PubMed  Google Scholar 

  9. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55(5):569–580.

    Article  CAS  PubMed  Google Scholar 

  10. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343(18):1290–1297.

    Article  CAS  PubMed  Google Scholar 

  11. Fudala PJ, Bridge TP, Chiang CN, Leiderman DB. A multi-site efficacy evaluation of a buprenor-phine/naloxone product for opiate dependence treatment. NIDA Res Monogr 1998; 179(105).

    Google Scholar 

  12. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40(1):17–25.

    Article  CAS  PubMed  Google Scholar 

  13. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Jr., Kintaudi P et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93(4):475–486.

    Article  CAS  PubMed  Google Scholar 

  14. Ahmadi J. Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. J Subst Abuse Treat 2003; 24(3):217–220.

    Article  PubMed  Google Scholar 

  15. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267(20):2750–2755.

    Article  CAS  PubMed  Google Scholar 

  16. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993; 181(6):358–364.

    Article  CAS  PubMed  Google Scholar 

  17. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53(5):401–407.

    CAS  PubMed  Google Scholar 

  18. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98(4):441–452.

    Article  PubMed  Google Scholar 

  19. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000; 60(1):39–50.

    Article  CAS  PubMed  Google Scholar 

  20. Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001; 62(1):97–104.

    Article  CAS  PubMed  Google Scholar 

  21. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs metha-done maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54(8):713–720.

    CAS  PubMed  Google Scholar 

  22. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994; 151(7):1025–1030.

    CAS  PubMed  Google Scholar 

  23. Sullivan M, Ferrell B. Ethical challenges in the management of chronic nonmalignant pain: negotiating through the cloud of doubt. J Pain 2005; 6(1):2–9.

    Article  PubMed  Google Scholar 

  24. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 2003; 70(Suppl. 2):S59–S77.

    Article  CAS  PubMed  Google Scholar 

  25. McNicholas L. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. A Treatment Improvement Protocol (TIP 40). 2004.

    Google Scholar 

  26. Chavez R, Amass L, Kamien JB, Prucha L. UCLA School of Medicine LAC, The Pain Institute at Little Company of Mary RBC, Friends Research Institute ILAC, editors. Buprenorphine Tablet Treatment for Opioid Dependence in Patients with Comorbid Chronic Severe Pain. 2004, June 14; CPDD 66th Annual Meeting, San Juan, PR.

    Google Scholar 

  27. Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000; 61(1):85–94.

    Article  CAS  PubMed  Google Scholar 

  28. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005; 100(2):197–205.

    Article  PubMed  Google Scholar 

  29. Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am J Addict 2004; 13 Suppl. 1:S17–S28.

    Article  PubMed  Google Scholar 

  30. SAMHSA/CSAT's Evaluation of the Buprenorphine Waiver Program. In: Stanton A, McLeod C, Kissin WB, Sonnefeld J, Luckey JW, editors. Evaluation of the Buprenorphine Waiver Program: Results from SAMHSA/CSAT's Evaluation of the Buprenorphine Waiver Program. 2005. College on Problems of Drug Dependence.

    Google Scholar 

  31. Lopatko OV, White JM, Huber A, Ling W. Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. Drug Alcohol Depend 2003; 69(3):317–322.

    Article  CAS  PubMed  Google Scholar 

  32. Kleppner SR, Patel R, McDonough J, Costantini LC. In-vitro and in-vivo characterization of a buprenorphine delivery system. J Pharm Pharmacol 2006; 58(3):295–302.

    Article  CAS  PubMed  Google Scholar 

  33. DSM-IV. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth edn. Arlington, VA: American Psychiatric Association, 2005.

    Google Scholar 

  34. Eriksen J, Jensen NH, Kamp-Jensen M, Bjarno H, Friis P, Brewster D. The systemic availability of buprenorphine administered by nasal spray. J Pharm Pharmacol 1989; 41(11):803–805.

    CAS  PubMed  Google Scholar 

  35. Kuhlman JJ, Jr., Lalani S, Magluilo J, Jr., Levine B, Darwin WD. Human pharmaco kinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996; 20(6): 369–378.

    CAS  PubMed  Google Scholar 

  36. Sigmon SC, Moody DE, Nuwayser ES, Bigelow GE. An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 2006; 101(3):420–432.

    Article  PubMed  Google Scholar 

  37. Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction 2004; 99(11):1439–1449.

    Article  PubMed  Google Scholar 

  38. Reidenberg B, Kennish L. A review of the effect of occlusive dressings on lamellar bodies in the stratum corneum and relevance to transdermal absorption. Dermatology Online Journal 11(3), 7. 2001.

    Google Scholar 

  39. Sobel BF, Sigmon SC, Walsh SL, Johnson RE, Liebson IA, Nuwayser ES et al. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend 2004; 73(1):11–22.

    Article  CAS  PubMed  Google Scholar 

  40. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R, O'Neil P. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol 2004; 9(1):59–65.

    Article  CAS  PubMed  Google Scholar 

  41. Bierer MF. Alcoholism in America: From Reconstruction to Prohibition. In: Tracy SW, editor. N Engl J Med 354(4), pp. 426–427. 2006. Johns Hopkins University Press.

    Google Scholar 

  42. NIAAA. National Institute on Alcohol Abuse and Alcoholism. Tenth Special Report to the U.S. Congress on Alcohol and Health. 2000. NIH Publication No. 00-1583, Bethesda, MD.

    Google Scholar 

  43. Corrao G, Bagnardi V, Zambon A, Arico S, Dall'Aglio C, Addolorato G et al. Outcome variables in the evaluation of alcoholics' treatment: lessons from the Italian Assessment of Alcoholism Treatment (ASSALT) Project. Alcohol Alcohol 1999; 34(6):873–881.

    CAS  PubMed  Google Scholar 

  44. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depend 2004; 74(3):223–234.

    Article  PubMed  Google Scholar 

  45. Daley DC, Marlatt GA. Relapse prevention. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, editors. Substance Abuse: A Comprehensive Textbook. Philadelphia, PA: Wippincott Williams & Wilkins, 2005: 772–785.

    Google Scholar 

  46. Johnson BA, Ait-Daoud N, Aubin HJ, Van Den BW, Guzzetta R, Loewy J et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone [Vivitrex(R)] in patients with alcohol dependence. Alcohol Clin Exp Res 2004; 28(9):1356–1361.

    Article  CAS  PubMed  Google Scholar 

  47. Addolorato G, Leggio L, Abenavoli L, Gasbarrini G. Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addict Behav 2005; 30(6):1209–1224.

    Article  PubMed  Google Scholar 

  48. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986; 256(11):1449–1455.

    Article  CAS  PubMed  Google Scholar 

  49. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 1997; 54(12):1130–1135.

    CAS  PubMed  Google Scholar 

  50. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 1992; 49(11):881–887.

    PubMed  Google Scholar 

  51. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49(11):876–880.

    CAS  PubMed  Google Scholar 

  52. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345(24):1734–1739.

    Article  CAS  PubMed  Google Scholar 

  53. Davis VE, Walsh MJ. Alcohol, amines, and alkaloids: a possible biochemical basis for alcohol addiction. Science 1970; 167(920):1005–1007.

    Article  CAS  PubMed  Google Scholar 

  54. Reid LD, Delconte JD, Nichols ML, Bilsky EJ, Hubbell CL. Tests of opioid deficiency hypotheses of alcoholism. Alcohol 1991; 8(4):247–257.

    Article  CAS  PubMed  Google Scholar 

  55. Sinclair JD, Adkins J, Walker S. Morphine-induced suppression of voluntary alcohol drinking in rats. Nature 1973; 246(5,433):425–427.

    Article  CAS  PubMed  Google Scholar 

  56. Tabakoff B, Hoffman PL. Alcohol interactions with brain opiate receptors. Life Sci 1983; 32(3):197–204.

    Article  CAS  PubMed  Google Scholar 

  57. O'Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R, Meyer RE et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 1996; 53(3):217–224.

    PubMed  Google Scholar 

  58. Oslin D, Liberto JG, O'Brien J, Krois S, Norbeck J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 1997; 5(4):324–332.

    Article  CAS  PubMed  Google Scholar 

  59. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 1997; 54(8):737–742.

    CAS  PubMed  Google Scholar 

  60. Physicians' Desk Reference. PDR Staff. 51st edn. 1997; 957–959.

    Google Scholar 

  61. Mark TL, Kranzler HR, Poole VH, Hagen CA, McLeod C, Crosse S. Barriers to the use of medications to treat alcoholism. Am J Addict 2003; 12(4):281–294.

    PubMed  Google Scholar 

  62. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamp-rosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997; 171:73–77.

    Article  CAS  PubMed  Google Scholar 

  63. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996; 53(8):673–680.

    CAS  PubMed  Google Scholar 

  64. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized mul-ticentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30(2):239–247.

    CAS  PubMed  Google Scholar 

  65. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation. J Psychiatr Res 2006; 40(5):383–393.

    Article  PubMed  Google Scholar 

  66. De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 2005; 19(6):517–537.

    Article  PubMed  Google Scholar 

  67. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60(1):92–99.

    Article  CAS  PubMed  Google Scholar 

  68. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295(17):2003–2017.

    Article  CAS  PubMed  Google Scholar 

  69. Fudala PJ, Heishman SJ, Henningfield JE, Johnson RE. Human pharmacology and abuse potential of nalmefene. Clin Pharmacol Ther 1991; 49(3):300–306.

    Article  CAS  PubMed  Google Scholar 

  70. Dixon R, Howes J, Gentile J, Hsu HB, Hsiao J, Garg D et al. Nalmefene: intravenous safety and kinetics of a new opioid antagonist. Clin Pharmacol Ther 1986; 39(1):49–53.

    Article  CAS  PubMed  Google Scholar 

  71. Michel ME, Bolger G, Weissman BA. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 1985; 7(4):175–177.

    CAS  PubMed  Google Scholar 

  72. Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 2005; 30(12):2254–2262.

    Article  CAS  PubMed  Google Scholar 

  73. Chow BL, Sellers EM, Tomkins DM. Effect of naltrexone and its derivatives, nalmefene and naltrindole, on conditioned anticipatory behaviour and saccharin intake in rats. Behav Pharmacol 1997; 8(8):725–735.

    Article  CAS  PubMed  Google Scholar 

  74. Hubbell CL, Marglin SH, Spitalnic SJ, Abelson ML, Wild KD, Reid LD. Opioidergic, sero-tonergic, and dopaminergic manipulations and rats' intake of a sweetened alcoholic beverage. Alcohol 1991; 8(5):355–367.

    Article  CAS  PubMed  Google Scholar 

  75. June HL, Grey C, Warren-Reese C, Durr LF, Ricks-Cord A, Johnson A et al. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res 1998; 22(9):2174–2185.

    CAS  PubMed  Google Scholar 

  76. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994; 18(5):1162–1167.

    Article  CAS  PubMed  Google Scholar 

  77. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999; 56(8):719–724.

    Article  CAS  PubMed  Google Scholar 

  78. Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 2004; 24(4):421–428.

    Article  CAS  PubMed  Google Scholar 

  79. Drobes DJ, Anton RF, Thomas SE, Voronin K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 2004; 28(9):1362–1370.

    Article  CAS  PubMed  Google Scholar 

  80. Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006; 163(2):303–312.

    Article  PubMed  Google Scholar 

  81. Johnsen J, Morland J. Disulfiram implant: a double-blind placebo controlled follow-up on treatment outcome. Alcohol Clin Exp Res 1991; 15(3):532–536.

    Article  CAS  PubMed  Google Scholar 

  82. Whyte CR, O'Brien PM. Disulfiram implant: a controlled trial. Br J Psychiatry 1974; 124(578): 42–44.

    Article  CAS  PubMed  Google Scholar 

  83. Wilson A, Davidson WJ, White J. Disulfiram implantation: placebo, psychological deterrent, and pharmacological deterrent effects. Br J Psychiatry 1976; 129:277–280.

    Article  CAS  PubMed  Google Scholar 

  84. Wilson A, Davidson WJ, Blanchard R, White J. Disulfiram implantation. A placebo-controlled trial with two-year follow-up. J Stud Alcohol 1978; 39(5):809–819.

    CAS  PubMed  Google Scholar 

  85. Wilson A, Davidson WJ, Blanchard R. Disulfiram implantation: a trial using placebo implants and two types of controls. J Stud Alcohol 1980; 41(5):429–436.

    CAS  PubMed  Google Scholar 

  86. Misra AL, Pontani RB. An improved long-acting delivery system for narcotic antagonists. NIDA Res Monogr 1981; 28:254–264.

    CAS  PubMed  Google Scholar 

  87. Schwope AD, Wise DL, Howes JF. Development of polylactic/glycolic acid delivery systems for use in treatment of narcotic addiction. Natl Inst Drug Abuse Res Monogr Ser 1975; (4):13–18.

    Google Scholar 

  88. Yoburn BC, Cohen AH, Inturrisi CE. Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat. J Pharmacol Exp Ther 1986; 237(1):126–130.

    CAS  PubMed  Google Scholar 

  89. Hamilton RJ, Olmedo RE, Shah S, Hung OL, Howland MA, Perrone J et al. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad Emerg Med 2002; 9(1):63–68.

    Article  PubMed  Google Scholar 

  90. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293(13):1617–1625.

    Article  CAS  PubMed  Google Scholar 

  91. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: A multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004; 28(7):1051–1059.

    Article  CAS  PubMed  Google Scholar 

  92. Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D et al. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 1987; 27(3):233–239.

    CAS  PubMed  Google Scholar 

  93. Costantini LC, Kleppner SR, McDonough J, Azar MR, Patel R. Implantable technology for long-term delivery of nalmefene for treatment of alcoholism. Int J Pharm 2004; 283(1–2):35–44.

    Article  CAS  PubMed  Google Scholar 

  94. Bibbiani F, Costantini LC, Patel R, Chase TN. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 2005; 192(1):73–78.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Accera, Inc. Clinical Development, 380 Interlocken Crescent, Suite 780, Broomfield, CO, 80021

    Lauren C. Costantini

Authors
  1. Lauren C. Costantini
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Life Sciences/Toxicology, Alkermes, Inc., Cambridge, MA, 02139, USA

    Reginald L. Dean III

  2. Department of Pharmacology, College of Osteopathic Medicine, University of New England, Biddleford, ME, 04005, USA

    Edward J. Bilsky

  3. Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA

    S. Stevens Negus

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Costantini, L.C. (2009). The Development of ProNeura Technology for the Treatment of Addictions. In: Dean, R.L., Bilsky, E.J., Negus, S.S. (eds) Opiate Receptors and Antagonists. Contemporary Neuroscience. Humana Press. https://doi.org/10.1007/978-1-59745-197-0_37

Download citation

Publish with us

Policies and ethics

Search

Navigation